Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole blood immune cell components to the prognosis of...

Descripción completa

Detalles Bibliográficos
Autores: Perez-Navarro, Enrique, Conteduca, Vincenza, Funes, Juan M., Dominguez, Jose I., Martin-Serrano, Miguel, Cremaschi, Paolo, Fernandez-Perez, Maria Piedad, Gordoa, Teresa Alonso, Font, Albert, Vázquez-Estévez, Sergio, González-del-Alba, Aránzazu, Wetterskog, Daniel, Mellado, Begona, Fernandez-Calvo, Ovidio, Méndez-Vidal, María José, Climent, Miguel Angel, Duran, Ignacio, Gallardo, Enrique, Rodriguez Sanchez, Angel, Santander, Carmen, Sáez, Maria Isabel, Puente, Javier, Tudela, Julian, Marinas, Cecilia, López-Andreo, María Jose, Castellano, Daniel, Attard, Gerhardt, Grande, Enrique, Rosino, Antonio, Botia, Juan A., Palma-Mendez, Jose, De Giorgi, Ugo, Gonzalez-Billalabeitia, Enrique
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Francisco de Vitoria
Repositorio:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
Idioma:inglés
OAI Identifier:oai:ddfv.ufv.es:10641/7674
Acceso en línea:https://hdl.handle.net/10641/7674
Access Level:acceso abierto
Palabra clave:castration-resistant prostate cancer (CRPC)
enzalutamide
prognostic factors
prostate cancer
whole blood
Oncology
Cancer Research
SDG 3 - Good Health and Well-being
Yes
yes
Descripción
Sumario:The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole blood immune cell components to the prognosis of these patients. This study analyzed pre-treatment blood samples from 152 chemotherapy-naive mCRPC patients participating in a phase 2 clinical trial (NCT02288936) and a validation cohort. We used CIBERSORT-X to quantify 22 immune cell types and assessed their prognostic significance using Kaplan–Meier and Cox regression analyses. Reduced CD8 T-cell proportions and elevated monocyte levels were substantially connected with a worse survival. High monocyte counts correlated with a median survival of 32.2 months versus 40.3 months for lower counts (HR: 1.96, 95% CI 1.11–3.45). Low CD8 T-cell levels were associated with a median survival of 31.8 months compared to 40.3 months for higher levels (HR: 1.97, 95% CI 1.11–3.5). These findings were consistent in both the trial and validation cohorts. Multivariate analysis further confirmed the independent prognostic value of CD8 T-cell counts. This study highlights the prognostic implications of specific blood immune cells, suggesting they could serve as biomarkers in mCRPC patient management and should be further explored in clinical trials.

Similares en LA Referencia